Eli Lilly is scaling back manufacturing of Cymbalta but says there will be no major loss of production jobs as a number of firms begin producing generic versions.
Wyeth’s battles to protect the controlled-release (CR) version of its anti-depressant Effexor are a sign of things to come according to a new Espicom report identifying 30 CR drugs likely to face competition.
Wyeth's manufacturing facility in Rouses Point, New York, has been
spared the scrap heap, with yesterday's announcement that new
pharma player Akrimax has bought up the beleaguered site.
Although the Canadian drug delivery specialist yesterday released
third quarter results showing revenues down on last year, operating
income is on the up despite generic competition and recent stumbles
for its antidepressant candidate.
Wyeth executives are remaining positive Pristiq (desvenlafaxine)
will eventually be approved as a treatment both for depression and
vasomotor symptoms associated with menopause despite recent
setbacks.
Food and Drug Administration (FDA) staffing and timetabling
problems have delayed the re-inspection of Wyeth's Puerto Rico
site, the company said this week.
Wyeth has boosted production at the US plant it has earmarked for
closure while it is dealing with ongoing manufacturing deficiencies
in its Puerto Rico facility.
